Improving the outcome of adoptive cell transfer by targeting tumor escape

Karen M. Kaluza, Richard Geoffrey Vile

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Adoptive T-cell transfer is among the most promising immunotherapies against cancer. To continue increasing the potential of this therapy, our studies focus on the inhibition of tumor recurrence. Recently, we have demonstrated several ways in which combination therapies involving multiple T-cell populations and immunostimulatory chemotherapy can enhance long-term survival.

Original languageEnglish (US)
Article numbere22059
JournalOncoImmunology
Volume2
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Tumor Escape
Adoptive Transfer
T-Lymphocytes
Immunotherapy
Neoplasms
Recurrence
Drug Therapy
Therapeutics
Population

Keywords

  • Adoptive T cell therapy
  • Cyclophosphamide
  • Immunostimulatory chemotherapy
  • Melanoma
  • Tumor escape

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Improving the outcome of adoptive cell transfer by targeting tumor escape. / Kaluza, Karen M.; Vile, Richard Geoffrey.

In: OncoImmunology, Vol. 2, No. 1, e22059, 01.2013.

Research output: Contribution to journalArticle

@article{8c65cbe5636e4553aecc5175bd227033,
title = "Improving the outcome of adoptive cell transfer by targeting tumor escape",
abstract = "Adoptive T-cell transfer is among the most promising immunotherapies against cancer. To continue increasing the potential of this therapy, our studies focus on the inhibition of tumor recurrence. Recently, we have demonstrated several ways in which combination therapies involving multiple T-cell populations and immunostimulatory chemotherapy can enhance long-term survival.",
keywords = "Adoptive T cell therapy, Cyclophosphamide, Immunostimulatory chemotherapy, Melanoma, Tumor escape",
author = "Kaluza, {Karen M.} and Vile, {Richard Geoffrey}",
year = "2013",
month = "1",
doi = "10.4161/onci.22059",
language = "English (US)",
volume = "2",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Improving the outcome of adoptive cell transfer by targeting tumor escape

AU - Kaluza, Karen M.

AU - Vile, Richard Geoffrey

PY - 2013/1

Y1 - 2013/1

N2 - Adoptive T-cell transfer is among the most promising immunotherapies against cancer. To continue increasing the potential of this therapy, our studies focus on the inhibition of tumor recurrence. Recently, we have demonstrated several ways in which combination therapies involving multiple T-cell populations and immunostimulatory chemotherapy can enhance long-term survival.

AB - Adoptive T-cell transfer is among the most promising immunotherapies against cancer. To continue increasing the potential of this therapy, our studies focus on the inhibition of tumor recurrence. Recently, we have demonstrated several ways in which combination therapies involving multiple T-cell populations and immunostimulatory chemotherapy can enhance long-term survival.

KW - Adoptive T cell therapy

KW - Cyclophosphamide

KW - Immunostimulatory chemotherapy

KW - Melanoma

KW - Tumor escape

UR - http://www.scopus.com/inward/record.url?scp=84886944594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886944594&partnerID=8YFLogxK

U2 - 10.4161/onci.22059

DO - 10.4161/onci.22059

M3 - Article

AN - SCOPUS:84886944594

VL - 2

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

M1 - e22059

ER -